Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -70.79 Million SEK | 45.78% |
| 2022 | -53.85 Million SEK | -67.41% |
| 2021 | -32.91 Million SEK | -74.12% |
| 2020 | -19.01 Million SEK | -75.91% |
| 2019 | -10.81 Million SEK | -6.05% |
| 2018 | -9.78 Million SEK | -40.94% |
| 2017 | -6.19 Million SEK | -15.6% |
| 2016 | -5.35 Million SEK | -63.88% |
| 2015 | -3.26 Million SEK | -286.13% |
| 2014 | -846.59 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.63 Million SEK | -1014.14% |
| 2024 Q1 | -1.06 Million SEK | 82.57% |
| 2023 Q3 | -2.72 Million SEK | 57.63% |
| 2023 Q4 | -1.76 Million SEK | 35.27% |
| 2023 FY | - SEK | 45.78% |
| 2023 Q1 | -5.26 Million SEK | 64.51% |
| 2023 Q2 | -6.42 Million SEK | -22.08% |
| 2022 Q2 | -13.42 Million SEK | -31.86% |
| 2022 FY | - SEK | -67.41% |
| 2022 Q4 | -14.82 Million SEK | -64.14% |
| 2022 Q3 | -9.03 Million SEK | 32.7% |
| 2022 Q1 | -10.18 Million SEK | 7.34% |
| 2021 Q2 | -6.52 Million SEK | -32.57% |
| 2021 Q1 | -4.91 Million SEK | 21.18% |
| 2021 FY | - SEK | -74.12% |
| 2021 Q4 | -10.98 Million SEK | -85.36% |
| 2021 Q3 | -5.92 Million SEK | 9.11% |
| 2020 FY | - SEK | -75.91% |
| 2020 Q1 | -2.38 Million SEK | 43.84% |
| 2020 Q3 | -2.45 Million SEK | 52.94% |
| 2020 Q4 | -6.24 Million SEK | -154.42% |
| 2020 Q2 | -5.21 Million SEK | -118.99% |
| 2019 Q2 | -1.25 Million SEK | 44.2% |
| 2019 Q1 | -2.24 Million SEK | 37.9% |
| 2019 FY | - SEK | -6.05% |
| 2019 Q3 | -1.51 Million SEK | -20.64% |
| 2019 Q4 | -4.23 Million SEK | -179.92% |
| 2018 Q3 | -1.35 Million SEK | 29.73% |
| 2018 Q1 | -1.81 Million SEK | -4.25% |
| 2018 Q2 | -1.93 Million SEK | -6.62% |
| 2018 Q4 | -3.62 Million SEK | -166.49% |
| 2018 FY | - SEK | -40.94% |
| 2017 Q2 | -1.77 Million SEK | -10.88% |
| 2017 FY | - SEK | -15.6% |
| 2017 Q4 | -1.74 Million SEK | -61.26% |
| 2017 Q3 | -1.07 Million SEK | 39.18% |
| 2017 Q1 | -1.6 Million SEK | 14.17% |
| 2016 Q1 | -1.28 Million SEK | 5.43% |
| 2016 Q2 | -1.13 Million SEK | 12.27% |
| 2016 FY | - SEK | -63.88% |
| 2016 Q4 | -1.86 Million SEK | -72.93% |
| 2016 Q3 | -1.07 Million SEK | 4.6% |
| 2015 Q3 | -911 Thousand SEK | -20.34% |
| 2015 Q1 | -238 Thousand SEK | -222.64% |
| 2015 Q2 | -757 Thousand SEK | -218.07% |
| 2015 Q4 | -1.36 Million SEK | -49.5% |
| 2015 FY | - SEK | -286.13% |
| 2014 Q3 | -44 Thousand SEK | -51.72% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q2 | -29 Thousand SEK | 0.0% |
| 2014 Q4 | 194.06 Thousand SEK | 541.05% |
| 2014 Q1 | -29 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -417.062% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | -86.941% |
| BioGaia AB (publ) | 466.19 Million SEK | 115.185% |
| Enzymatica AB (publ) | -41.12 Million SEK | -72.149% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | -64.428% |
| Gabather AB (publ) | 37 Thousand SEK | 191427.027% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -379.289% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | -162.584% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -473.671% |
| ODI Pharma AB | 1.36 Million SEK | 5277.191% |
| Orexo AB (publ) | -22 Million SEK | -221.777% |
| Probi AB (publ) | 115.61 Million SEK | 161.232% |
| Swedencare AB (publ) | 484 Million SEK | 114.626% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.979% |
| Toleranzia AB | -7.39 Million SEK | -856.894% |
| Vivesto AB | -89.75 Million SEK | 21.131% |